ECSP21033236A - Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp - Google Patents

Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp

Info

Publication number
ECSP21033236A
ECSP21033236A ECSENADI202133236A ECDI202133236A ECSP21033236A EC SP21033236 A ECSP21033236 A EC SP21033236A EC SENADI202133236 A ECSENADI202133236 A EC SENADI202133236A EC DI202133236 A ECDI202133236 A EC DI202133236A EC SP21033236 A ECSP21033236 A EC SP21033236A
Authority
EC
Ecuador
Prior art keywords
compounds
nlrp
compositions
activity
treatment
Prior art date
Application number
ECSENADI202133236A
Other languages
English (en)
Inventor
Dong-Ming Shen
Jason Katz
Shomir Ghosh
Gary Glick
Hans Martin Seidel
William Roush
Shankar Venkatraman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP21033236A publication Critical patent/ECSP21033236A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

En un aspecto, se presentan compuestos de la Fórmula AA, o una de sus sales farmacéuticamente aceptables: Fórmula AA, o una de sus sales farmacéuticamente aceptables, en donde las variables que se muestran en la Fórmula A pueden definirse como en cualquier lugar del presente documento.
ECSENADI202133236A 2018-11-13 2021-05-11 Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp ECSP21033236A (es)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201862760209P 2018-11-13 2018-11-13
US201862760248P 2018-11-13 2018-11-13
US201862760244P 2018-11-13 2018-11-13
US201862768811P 2018-11-16 2018-11-16
US201862769165P 2018-11-19 2018-11-19
US201862769151P 2018-11-19 2018-11-19
US201962795919P 2019-01-23 2019-01-23
US201962796356P 2019-01-24 2019-01-24
US201962796361P 2019-01-24 2019-01-24
US201962836585P 2019-04-19 2019-04-19
US201962836577P 2019-04-19 2019-04-19
US201962836575P 2019-04-19 2019-04-19
US201962895595P 2019-09-04 2019-09-04

Publications (1)

Publication Number Publication Date
ECSP21033236A true ECSP21033236A (es) 2021-06-30

Family

ID=68841175

Family Applications (2)

Application Number Title Priority Date Filing Date
ECSENADI202133236A ECSP21033236A (es) 2018-11-13 2021-05-11 Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
ECSENADI202444340A ECSP24044340A (es) 2018-11-13 2024-06-07 Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp

Family Applications After (1)

Application Number Title Priority Date Filing Date
ECSENADI202444340A ECSP24044340A (es) 2018-11-13 2024-06-07 Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp

Country Status (32)

Country Link
US (1) US20230031406A1 (es)
EP (2) EP4667054A3 (es)
JP (2) JP7730759B2 (es)
KR (1) KR20210096123A (es)
CN (2) CN113166065B (es)
AU (1) AU2019379109B2 (es)
BR (1) BR112021008969A2 (es)
CA (1) CA3114918A1 (es)
CL (1) CL2021001228A1 (es)
CO (1) CO2021006075A2 (es)
CR (1) CR20210235A (es)
DK (1) DK3880660T3 (es)
EC (2) ECSP21033236A (es)
ES (1) ES3042546T3 (es)
FI (1) FI3880660T3 (es)
HR (1) HRP20251344T1 (es)
HU (1) HUE073575T2 (es)
IL (1) IL283042B2 (es)
JO (1) JOP20210105B1 (es)
LT (1) LT3880660T (es)
MA (1) MA54229B1 (es)
MX (1) MX2021005529A (es)
MY (1) MY206733A (es)
PE (1) PE20211698A1 (es)
PH (1) PH12021500025A1 (es)
PL (1) PL3880660T3 (es)
PT (1) PT3880660T (es)
RS (1) RS67257B1 (es)
SG (1) SG11202103405TA (es)
SI (1) SI3880660T1 (es)
TW (1) TWI914296B (es)
WO (1) WO2020102096A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3649112A1 (en) * 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
TW201910316A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
EP3668843A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
EP3707137A1 (en) 2017-11-09 2020-09-16 Inflazome Limited Novel sulfonamide carboxamide compounds
PE20210050A1 (es) 2017-11-09 2021-01-08 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
BR112021001044A2 (pt) 2018-07-20 2021-04-13 F. Hoffmann-La Roche Ag Compostos de sulfonimidamida como inibidores da atividade de interleucina-1
CA3158123A1 (en) * 2019-11-12 2021-05-20 Yonggang Wei Amide derivative and preparation method therefore and use thereof in medicine
JP7843705B2 (ja) * 2020-01-22 2026-04-10 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物
WO2022023907A1 (en) 2020-07-31 2022-02-03 Novartis Ag Methods of selecting and treating patients at elevated risk of major adverse cardiac events
EP4293018A4 (en) * 2021-02-10 2025-04-30 Hangzhou Innogate Pharma Co., Ltd. COMPOUND AS NLRP3 INHIBITOR
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
CN116635374B (zh) * 2021-05-10 2025-05-06 康百达（四川）生物医药科技有限公司 酰胺衍生物及其应用
CN116917282A (zh) * 2021-05-10 2023-10-20 成都百裕制药股份有限公司 酰胺衍生物及其应用
TW202246230A (zh) * 2021-05-10 2022-12-01 大陸商成都百裕製藥股份有限公司 醯胺衍生物及其應用
CN114989058B (zh) * 2022-06-02 2024-04-16 中国科学院成都生物研究所 一种手性氯代砜亚胺类化合物及其衍生物的制备方法
CN115974745B (zh) * 2022-12-27 2025-06-03 瑞石生物医药有限公司 一类含引达省的化合物及其医药用途
CN116253664A (zh) * 2023-02-01 2023-06-13 山东海科创新研究院有限公司 基于双液相微乳化缩合工艺的accp制备方法
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055755T2 (hu) * 2015-02-16 2021-12-28 Univ Queensland Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk
US11339136B2 (en) * 2016-04-18 2022-05-24 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
HUE066566T2 (hu) * 2017-07-24 2024-08-28 Novartis Ag Vegyületek és készítmények NLRP aktivitással összefüggõ állapotok kezelésére
EP3658538B1 (en) * 2017-07-24 2023-04-19 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
BR112021001044A2 (pt) * 2018-07-20 2021-04-13 F. Hoffmann-La Roche Ag Compostos de sulfonimidamida como inibidores da atividade de interleucina-1

Also Published As

Publication number Publication date
IL283042B2 (en) 2024-12-01
MA54229B1 (fr) 2025-09-30
FI3880660T3 (fi) 2025-10-02
MA54229A (fr) 2022-02-16
MX2021005529A (es) 2021-06-18
ECSP24044340A (es) 2024-07-31
CL2021001228A1 (es) 2021-12-31
IL283042B1 (en) 2024-08-01
MY206733A (en) 2025-01-03
AU2019379109A1 (en) 2021-05-06
US20230031406A1 (en) 2023-02-02
LT3880660T (lt) 2025-10-10
TW202031647A (zh) 2020-09-01
CR20210235A (es) 2021-06-30
SG11202103405TA (en) 2021-05-28
EP4667054A3 (en) 2026-02-18
CN113166065A (zh) 2021-07-23
JOP20210105B1 (ar) 2024-12-22
JP2024113083A (ja) 2024-08-21
JP7730759B2 (ja) 2025-08-28
DK3880660T3 (da) 2025-10-06
CO2021006075A2 (es) 2021-05-31
PE20211698A1 (es) 2021-09-01
CA3114918A1 (en) 2020-05-22
PT3880660T (pt) 2025-10-21
TWI914296B (zh) 2026-02-11
BR112021008969A2 (pt) 2021-08-03
RS67257B1 (sr) 2025-10-31
SI3880660T1 (sl) 2025-11-28
HRP20251344T1 (hr) 2025-12-19
CN113166065B (zh) 2025-04-15
EP3880660A1 (en) 2021-09-22
AU2019379109B2 (en) 2022-07-07
HUE073575T2 (hu) 2026-01-28
WO2020102096A1 (en) 2020-05-22
EP3880660B1 (en) 2025-07-02
KR20210096123A (ko) 2021-08-04
PL3880660T3 (pl) 2025-11-12
PH12021500025A1 (en) 2022-05-02
JOP20210105A1 (ar) 2023-01-30
EP4667054A2 (en) 2025-12-24
ES3042546T3 (en) 2025-11-21
CN120531732A (zh) 2025-08-26
IL283042A (en) 2021-06-30
JP2022507065A (ja) 2022-01-18

Similar Documents

Publication Publication Date Title
CO2021006075A2 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
CL2020000215A1 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp.
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
CO2018013293A2 (es) Derivados de pirazolopirimidina como inhibidor de quinasa
CO2017013065A2 (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
NI201600071A (es) Compuestos de inhibidor de autotaxina
CO2019005059A2 (es) Inhibidores de magl
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
CR20160544A (es) Compuesto heterocíclico que contiene nitrógeno
CO2019005038A2 (es) Inhibidores de magl
MX2017006224A (es) Derivados heterociclicos y usos de los mismos.
JOP20210050A1 (ar) معدلات تعبير pnpla3
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
BR112017000730A2 (pt) derivados de pirrolidinona como inibidores de metap-2
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CO2018001237A2 (es) Derivados de apramicina efectivos contra bacterias resistentes a múltiples fármacos y composiciones de los mismos
CO2019007836A2 (es) Derivados de pirrolotriazina como inhibidor de cinasas
MX2016014701A (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
CL2020000586A1 (es) Moduladores de la expresión de enac.
DOP2021000090A (es) Compuestosy composicionespara el tratamientode afecciones asociadas con la actividad de nlrp
CL2018002347A1 (es) Nuevos derivados pirrolidina
MX2019006886A (es) Métodos para tratar enfermedades asociadas con células linfoides innatas del grupo 2 (ilc2).
MX2019000006A (es) Composiciones para el tratamiento de estrias y ulceras de origen isquemico.